Trial Profile
A Long-term Study of OPC-262 in Patients With Type 2 Diabetes.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 Jul 2019
Price :
$35
*
At a glance
- Drugs Saxagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Therapeutic Use
- Sponsors Kyowa Hakko Kirin; Kyowa Kirin; Otsuka Pharmaceutical
- 12 Apr 2012 Actual end date Jul 2011 added as reported by ClinicalTrials.gov.
- 12 Apr 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 16 Jan 2010 New trial record